RxDoctor Payments Data

Evan Howard, DO

Internal Medicine · Alcoa, TNNPI 1831728955

Payments from drug & device makers

$761in general payments, 2019–2025

Across 43 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$144
  • AstraZeneca$111
  • GSK$107
  • Boehringer Ingelheim$65
  • Pfizer$58
  • Xeris Pharmaceuticals, Inc.$53
  • plus $224 from 9 others

What the payments were for

  • Food & beverage$761100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$761 in reported general payments places this provider in the 65th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$76,353
Medicare patients
270
Services billed
1,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide134$156,178
EliquisApixaban114$83,152
JardianceEmpagliflozin51$53,161
XareltoRivaroxaban20$19,939
FarxigaDapagliflozin Propanediol17$19,025
Repatha SureclickEvolocumab15$18,964
MounjaroTirzepatide18$17,883
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,413
MyrbetriqMirabegron16$12,627
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$8,730
JanumetSitagliptin Phos/Metformin Hcl15$8,078
Tresiba Flextouch U-100Insulin Degludec16$6,193
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$3,110
Albuterol Sulfate HfaAlbuterol Sulfate87$2,976
Levothyroxine Sodium180$2,075

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$144$156,178134 claims
PfizerEliquis$58$83,152114 claims
Boehringer IngelheimJardiance$65$53,16151 claims
AstraZenecaFarxiga, Breztri Aerosphere$111$27,75531 claims
Johnson & JohnsonXarelto$33$19,93920 claims
Lilly USA, LLCMounjaro$13$17,88318 claims
GSKTrelegy Ellipta$107$15,41320 claims
Astellas Pharma US IncMyrbetriq$17$12,62716 claims
MerckJanumet$28$8,07815 claims
AbbVieSynthroid$38$1,67620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Alcoa

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →